Home  Clinical trials Tomudex (raltitrexed)
|
|
Tomudex (raltitrexed) is an injectable cytotoxic agent for advanced colorectal cancer. Tomudex was developed as part of a collaboration with the Institute for Cancer Research in the UK and the British Technology Group.
Please consult the prescribing information for the country concerned for guidance on the approved use of Tomudex (raltitrexed). | Study Number | Completed Clinical Trial Report Summaries | PETACC | Pan-European Trials in Adjuvant Colon Cancer (PETACC-1) Randomized Phase III trial of Tomudex (Raltitrexed) vs. Standard Leucovorin modulated bolus 5-FU in patients with Dukes’ stage C colon cancer. | 1694-TR01 | A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer. |
|
|
|
|